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Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic disorder which shares clinical and morphological features
of myelodysplastic syndrome and myeloproliferative neoplasms. Conventional therapeutic options include hydroxyurea,
hypomethylating agents, and systemic chemotherapy, which are all palliative measures and are associated with potential side
effects. Allogeneic hematopoietic cell transplantation is the only curative option. Natural health products such as papaya leaf
extract and dandelion root extract have been shown to demonstrate anticancer activity in preclinical and clinical studies, re-
spectively. We present a case study of a 76-year-old male with previously untreated CMML, whose hematological parameters
remained stable and whose bone marrow blast counts vastly improved while taking papaya leaf extract and dandelion root extract.
1. Introduction
Chronic myelomonocytic leukemia (CMML) is an aggres-
sive and generally resistant form of hematopoietic stem cell
neoplasm with the potential of progression to an acute
myelogenous leukemia and with a median survival of 12 to
24 months from diagnosis [1]. Because of lack of CMML-
specific clinical trials, the optimal treatment of CMML is
unclear. Allogeneic hematopoietic cell transplantation
(alloHCT) is the only disease-modifying therapy, but many
patients are not candidates for an alloHCT due to multiple
comorbidities and/or advanced age. Numerous anticancer
therapeutic agents have been derived from natural products
[2]. Research into the antimalignancy properties of natural
health products (NHPs) dates back to the 1980s. A handful
of preclinical studies have demonstrated anticancer activity
with the use of papaya leaf extra (PLE) and dandelion root
extract (DRE) [1, 2].
2. Case
A 76-year-old Caucasian male with a history of stage Ic
prostate cancer, gleason 3 + 3, status after radiotherapy and
antiandrogen therapy in 1998 (in remission), hypertension,
and IgG2/IgG4 subclass deficiency presented with CMML-1
with deletion 7q (q22q32) in 11 of 20 cells (55%) diagnosed
in December 2008. JAK 2 mutation analysis and quantitative
RT-PCR for the BCR-ABL transcript were negative. He had
an isolated thrombocytopenia at presentation, his diagnostic
bone marrow biopsy demonstrated trilineage hematopoiesis
without dysplasia and 1% blasts, and atypical intermediate-
sized monocytoid cells increased at 20%–30% of the bone
marrow cellularity. No systemic treatment was commenced
at the time. His other comorbidities include gastroesopha-
geal reflux disease, lumbar spinal stenosis (L3–L4), and
lumbar neuroforaminal narrowing due to degenerative disc
disease.
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In early 2009, he started PLE in the form of papaya leaf
tea, 4 grams once daily in the morning and one teaspoon of
elixir at night. He also had IgG2 and IgG4 subclass de-
ficiencies. For his IgG subclass deficiencies, he was treated
with cimetidine 400mg 2 times daily starting from October
2014. He also started DRE 520mg capsules, two capsules
once daily in early 2015. His bone marrow blasts peaked at
11% in October 2009 and have been less than 5% since
March 2013. Of note, both the papaya leaf extract and DRE
supplements were commercial products.
Prior to his diagnosis of CMML, he had been on nu-
merous over-the-counter supplements (commercial prod-
ucts): pomegranate XT 1mg daily; vitamin C 500mg daily;
L-carnitine, red yeast rice, niacin, vitamin B6, and omega-3
fatty acids (all started in the 1990s); nettle root daily, pyr-
roloquinoline 1 tablet daily, melatonin 1.5mg daily, beta-
glucan 400mg daily, and ellagic acid (all started in 2000);
and one red rooibos tea bag daily with the PLE tea. Following
the diagnosis of CMML, he started numerous additional
OTC supplements: vitamin K daily (2011); bio-curcumin
daily and vinpocetine 10mg daily (2011); inositol 500mg
daily (2012); resveratrol 1 tab bid, vitamin B12, folic acid,
and boswellia 100mg daily (2013); S-adenosylmethionine
(SAM-E) (2014) and rice bran 500mg bid (2014); and
maitake mushroom elixir about 2–3 cc once daily (2017). A
trend of his blood counts and bone marrow results are il-
lustrated in Table 1.
(e patient had no side effects and no worsening of
comorbidities attributable to the supplements. He was
hospitalized in June 2017 with acute hypoxemic respiratory
failure and reactive airways treated with antibiotics and
bronchodilators, which was not attributed to the supple-
ments. Additionally, he was not neutropenic (ANC was
always greater than 1200 cells/μL) during the hospitalization.
Clinically, he continues to feel well and his hematological
parameters remain consistently stable.
3. Discussion
(e World Health Organization (WHO) has classified
CMML as a myelodysplastic syndrome (MDS) overlapping
with a myeloproliferative disease (MPD) [3]. Its dismal
prognosis indicates a pressing need for more effective al-
ternatives therapies. (e use of NHPs may well provide a
nontoxic and less-expensive therapeutic alternative. Our
hypothesis is that our patient’s CMML disease course has
been modified by NHPs and OTC supplements. In vitro data
demonstrate anticancer activity with the use of PLE, DRE,
and curcumin [1, 4–6]. It is unclear whether any of the other
supplements have contributed to the stable disease course.
Table 1
Month/
year
Bone marrow
blast %
FISH deletion 7q % metaphases
or standard banding karyotype
(no. of positive cells/number of
metaphase examined)
WBC
(k/µL)
Hb (g/
dL)
Platelet
(k/µL)
ANC
(k/µL)
AMC
(k/µL)
IgA
(mg/
dL)
IgG
(mg/
dL)
IgM
(mg/dL)
12/
2008 1 11/20 4.7 14.7 122 1.91 1.51
05/
2009 8 4.3 15 101 1.55 1.38
10/
2009 11 52 (13/20) 3.4 15.8 75 0.94 1.43
03/
2010 8.5 (9/20) 5 16.5 73 1.5 1.76
10/
2010 4 75 4.5 17.2 88 1.25 1.99
12/
2011 4.9 16.5 1.08 1.71
03/
2012 8 75 4.2 16.7 70 1.34 1.80
03/
2013 <5 70 4 16.1 61 0.82 1.97
03/
2014 <5 89 4.2 15.9 73 0.86 2.27
03/
2015 5 95 5.2 15.4 84 1.56 2.55 111 661 59.3
03/
2016 3 93 4.8 15.3 71 1.41 2.03 106 637 49.1
03/
2017 4.8 100 5.5 16.2 70 1.68 2.25
09/
2017 7.2 15 70 2.16 3.5 100 572 50.3
12/
2017 5.1 14.8 76 1.29 4.67 130 659 51.2
2 Case Reports in Hematology
Nguyen et al. conducted a literature review on DRE
(Carica papaya) which was noted to have anti-
inflammatory and anticancer effects [4]. Otsuki et al.
demonstrated a significant growth inhibitory effect of the
Carica papaya extract on tumor cell lines [5]. (ey also
demonstrated a reduction in cytokines IL-2 and IL-4 in
peripheral blood mononuclear cells [5]. (ere are most
interesting findings; the PLE tea and elixir our patient
consumed may have had an antiproliferative effect on his
CMML.
One study demonstrated a selective efficacy of DRE
(Taraxacum officinale) in inducing apoptosis in CMML cell
lines [1]. DRE is a NHP proposed to contain antioxidant
properties; however, the exact mechanism of action in
cancer cells remains elusive [2]. Studies of DRE have
demonstrated a selective inhibition of the death receptor-
mediated pathway of apoptosis [2]. An additional widely
used NHP is turmeric (Curcuma longa) whose active in-
gredient is curcumin which has been studied for anti-
malignancy effects.
Arber et al. demonstrated selective efficacy in induction
of programmed cell death in aggressive and resistant
CMML cell lines using DRE [3]. Hamm et al. described a
case of a 70-year-old man with a history of primary re-
fractory acute myelomonocytic leukemia who received
DRE tea after failing induction chemotherapy [6]. What
emerged was a diagnosis of CMML. (e patient achieved a
complete hematological remission with the ongoing use of
DRE tea. When he drank less than three cups per day of the
DRE tea, his peripheral blood monocyte count started to
rise [6]. (e same group reported an elderly female with
CMML who only used DRE tea to treat her disease. She
achieved a hematological remission but relapsed 3 months
later [6]. (is group reported a third case of a 60-year-old
female with primary refractory acute myelomonocytic
leukemia and a subsequent diagnosis of CMML who
achieved a hematological remission after starting DRE tea,
three cups per day. She remains in complete hematological
remission at least 5 months after starting DRE tea. A fourth
patient with acute myeloid leukemia (AML), who was not a
candidate for intense systemic chemotherapy, was treated
with low-dose cytarabine followed by DRE tea. She de-
veloped peripheral blasts when she stopped the tea for one
month, but she continues the DRE tea 15 months from the
AML relapse [6].
4. Conclusion
NHPs may well provide a potential nontoxic therapeutic
alternative to conventional systemic therapy in the treat-
ment of CMML. Our patient remains on numerous NHPs,
most notably on PLE tea and DRE. He remains asymp-
tomatic, transfusion independent with stable counts. DRE
and PLEmay provide an improved quality of life of patients
with CMML if systemic chemotherapy can be avoided.
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